MEDP — Medpace Holdings, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

575.08

+1.79+0.31%

Overview Short InterestFilings

MEDPQT61Medpace Holdings, Inc.·NASDAQ

Overview Short InterestFilings

575.08+0.31%

Loading chart...

Signal & projected range

Analyst consensus risingHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RVTY-3.32%$111.39 GH+0.60%$159.79 ICLR-0.98%$156.85 CRL+1.41%$234.12 LH+1.60%$312.34 DGX+0.76%$233.72 WAT+5.69%$396.08 MTD-0.55%$1437.00

Snapshot

Index	-	P/E	33.69	EPS (ttm)	17.07	Insider Own	47.45%	Shs Outstand	27.91M	Perf Week	0.72%

Market Cap	16.05B	Forward P/E	29.72	EPS next Y	19.35	Insider Trans	-0.47%	Shs Float	22.48M	Perf Month	1.77%

Enterprise Value	15.67B	PEG	3.39	EPS next Q	4.39	Inst Own	-	Short Float	9.74%	Perf Quarter	37.90%

Income	491.00M	P/S	5.77	EPS this Y	3.12%	Inst Trans	-	Short Ratio	5.86	Perf Half Y	-2.23%

Sales	2.78B	P/B	36.99	EPS next Y	9.92%	ROA	23.89%	Short Interest	2.19M	Perf YTD	2.39%

Book/sh	15.55	P/C	31.91	EPS next 5Y	9.95%	ROE	110.15%	52W High	677.92 -15.17%	Perf Year	35.92%

Cash/sh	18.02	P/FCF	21.96	EPS past 3/5Y	28.04% 31.81%	ROIC	77.00%	52W Low	372.99 54.18%	Perf 3Y	125.69%

Dividend Est.	-	EV/EBITDA	26.03	Sales past 3/5Y	20.11% 22.26%	Gross Margin	28.76%	Volatility	3.18% 3.72%	Perf 5Y	236.03%

Dividend TTM	-	EV/Sales	5.63	EPS Y/Y TTM	35.15%	Oper. Margin	20.97%	ATR (14)	23.45	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	0.73	Sales Y/Y TTM	31.91%	Profit Margin	17.67%	RSI (14)	60.05	Recom	2.84

Dividend Gr. 3/5Y	-	Current Ratio	0.73	EPS Q/Q	37.10%	SMA20	3.42%	Beta	1.12	Target Price	598.89

Payout	0.00%	Debt/Eq	0.55	Sales Q/Q	17.25%	SMA50	12.71%	Rel Volume	0.67	Prev Close	573.29

Employees	6,200	LT Debt/Eq	0.50	Earnings	Oct 28	SMA200	10.89%	Avg Volume	341.37K	Price	575.08

IPO Date	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.84% 2.58%	Net Debt/EBITDA	-0.64	Volume	227,917	Change	0.31%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-24-26	Reiterated	Robert W. Baird		$547 → $624
Jul-24-26	Reiterated	Mizuho	Outperform	$586 → $665
Jul-24-26	Reiterated	RBC Capital	Outperform	$484 → $692
Jul-24-26	Reiterated	BMO Capital	Market Perform	$400 → $600
Jul-23-26	Reiterated	Barclays	Equal Weight	$450 → $600
Jul-23-26	Reiterated	Leerink Partners	Market Perform	$515 → $620
Jul-23-26	Reiterated	Deutsche Bank	Hold	$480 → $535
Jul-13-26	Reiterated	Mizuho	Outperform	$582 → $586
Jul-08-26	Reiterated	Robert W. Baird		$477 → $547
Jul-08-26	Downgrade	Baird	Outperform → Neutral

Latest News

Aug-04-26

Aug-04-2604:13AM

California State Teachers Retirement System Boosts Position in Medpace Holdings, Inc. $MEDPdefenseworld.net

Aug-03-26

Aug-03-2610:51AM

Why Medpace (MEDP) is a Top Momentum Stock for the Long-Termzacks.com

Jul-30-26

Jul-30-2611:01AM

Medpace Holdings President & CEO Trades $4.35M In Company StockBenzinga

Jul-29-26

Jul-29-2604:17AM

First Trust Advisors LP Sells 3,008 Shares of Medpace Holdings, Inc. $MEDPdefenseworld.net

Jul-28-26

Jul-28-2603:50AM

American Capital Management Inc. Has $104.66 Million Stock Holdings in Medpace Holdings, Inc. $MEDPdefenseworld.net

Jul-27-26

Jul-27-2601:46PM

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)zacks.com

Jul-26-26

Jul-26-2603:49AM

Dimensional Fund Advisors LP Sells 10,865 Shares of Medpace Holdings, Inc. $MEDPdefenseworld.net

Jul-25-26

Jul-25-2607:16AM

Medpace: Cancellations Are Normalizingseekingalpha.com

03:43AM

Arrowstreet Capital Limited Partnership Raises Stock Position in Medpace Holdings, Inc. $MEDPdefenseworld.net

Jul-24-26

Jul-24-2610:16AM

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?zacks.com

Jul-23-26

Jul-23-2602:15PM

Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlookbenzinga.com

12:47PM

Medpace: 'Buy' On Financial Metric Improvements And Solid Q2 2026 Earningsseekingalpha.com

12:20PM

Medpace Holdings, Inc. (MEDP) Q2 2026 Earnings Call Transcriptseekingalpha.com

11:08AM

Medpace Q2 Earnings Call Highlightsmarketbeat.com

Jul-22-26

Jul-22-2609:46PM

Medpace Notches A Big Bookings Beat, And Reverses Its First-Quarter MalaiseYahoo

Company

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,782	2,530	2,109	1,886	1,460	1,142	926	861	705
Cost of Goods Sold Incl. D&A	1,982	1,770	1,453	1,361	1,028	814	647	615	489
Gross Profit	800	761	656	525	432	328	279	246	216
Selling, General and Administrative Excl. Other	189	198	180	161	131	108	92	95	76
Research and Development	0	0	0	0	0	0	0	0	0
Other Operating Expense	28	28	29	27	23	22	20	23	38
Operating Income	584	535	447	337	279	199	167	127	101
Interest Expense	0	0	0	0	3	0	0	2	8
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	7	29	-1	7	3	1	-1	1
Net Income Before Taxes	600	542	476	336	283	202	169	125	94
Income Taxes	108	91	72	53	37	20	23	24	21
Consolidated Net Income	491	451	404	283	245	182	145	100	73
Net Income From Continuing Operations	491	451	404	283	245	182	145	100	73
Net Income	491	451	404	283	245	182	145	100	73
EPS (Recurring)	17.39	15.64	13.06	9.20	7.57	5.06	4.07	2.79	2.05
EPS (Basic, Before Extraordinaries)	17.39	15.64	13.06	9.20	7.57	5.06	4.07	2.79	2.05
EPS (Diluted)	17.07	15.28	12.63	8.88	7.28	4.81	3.84	2.67	1.97
EBITDA	602	571	505	362	308	223	187	150	140
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	33.69	36.76	26.30	34.52	29.18	45.25	36.25	31.48	26.87
Price To Sales Ratio	5.79	6.44	4.88	5.04	4.66	6.86	5.41	3.51	2.70
Gross Margin	28.76	30.08	31.10	27.84	29.59	28.72	30.13	28.57	30.64
Operating Margin	20.99	21.15	21.19	17.87	19.11	17.43	18.03	14.75	14.33
Net Margin	17.65	17.83	19.16	15.01	16.78	15.94	15.66	11.61	10.35
Shares Outstanding	28	29	31	31	32	36	36	36	36
Market Capitalization	16,102	16,288	10,299	9,502	6,797	7,835	5,011	3,026	1,905
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Troendle August J.	President & CEO	Jul 28 '26	Sale	600.01	3,510	2,106,035	638,946	Jul 29
BURWIG SUSAN E	Exec. VP, Operations	Jul 28 '26	Sale	600.00	7,500	4,500,000	62,984	Jul 29
Troendle August J.	President & CEO	Jul 27 '26	Sale	600.85	3,728	2,239,969	642,456	Jul 29
Carley Brian T	Director	Jun 30 '26	Option Exercise	0.00	36	0	32,825	Jul 02
McCarthy Cornelius P. III	Director	Jun 30 '26	Option Exercise	0.00	28	0	10,352	Jul 02
EWALD STEPHEN P	General Counsel & Corp. Secy.	May 28 '26	Option Exercise	138.87	16,349	2,270,386	36,692	Jun 01
EWALD STEPHEN P	General Counsel & Corp. Secy.	May 28 '26	Sale	450.00	16,349	7,357,050	20,343	Jun 01
EWALD STEPHEN P	General Counsel & Corp. Secy.	Apr 24 '26	Option Exercise	138.87	3,500	486,045	20,343	Apr 28
Brady Kevin M.	CFO & Treasurer	Apr 24 '26	Option Exercise	138.87	7,000	972,090	12,830	Apr 28
Kraft Robert O.	Director	Mar 31 '26	Option Exercise	0.00	33	0	922	Apr 02
McCarthy Cornelius P. III	Director	Mar 31 '26	Option Exercise	0.00	29	0	10,324	Apr 02
Carley Brian T	Director	Mar 31 '26	Option Exercise	0.00	36	0	32,789	Apr 02
BURWIG SUSAN E	Exec. VP, Operations	Mar 18 '26	Option Exercise	166.73	12,000	2,000,760	70,484	Mar 19
GEIGER JESSE J	President	Mar 17 '26	Option Exercise	138.87	31,707	4,403,151	46,707	Mar 19
GEIGER JESSE J	President	Mar 17 '26	Sale	455.30	31,707	14,436,197	15,000	Mar 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.